Ingvild Løberg Tangen1, Henrica M J Werner1, Anna Berg1, Mari K Halle1, Kanthida Kusonmano2, Jone Trovik1, Erling A Hoivik1, Gordon B Mills3, Camilla Krakstad1, Helga B Salvesen1. 1. Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Norway; Department of Gynecology and Obstetrics, Haukeland University Hospital, Norway. 2. Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Norway; Department of Gynecology and Obstetrics, Haukeland University Hospital, Norway; Computational Biology Unit, University of Bergen, Bergen, Norway. 3. Department of Systems Biology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Abstract
OBJECTIVE: In endometrial cancer loss of progesterone receptor (PR, gene name PGR) is associated with aggressive disease and altered response to hormonal treatment. The aim of this study was to investigate changes in PR expression level with disease progression, and explore whether differences in gene expression according to PR status can be linked to processes involved in cancer development elucidating new therapeutic opportunities. METHODS: 686 primary endometrial cancers and 171 metastatic lesions were investigated for PR expression in relation to clinical and histopathological data. Protein levels were investigated by immunohistochemistry and reverse phase protein array, and mRNA levels by DNA oligonucleotide microarray. RESULTS: PR protein level was significantly associated with PGR mRNA expression (P<0.001) and patient survival (P<0.001). Loss of PR increased with disease progression, with 23% of the primary tumours and 76% of metastases demonstrating PR loss. Using a cell cycle progression signature score, PR loss was associated with increased proliferation for both oestrogen receptor (ER) positive and negative tumours. Through a Connectivity Map search, CDK inhibitors and other drugs with anti-proliferative effects were suggested in particular for treatment of patients with loss of PR. CONCLUSION: Loss of PR in endometrial cancer is associated with increased proliferation, poor survival, and increases from primary to metastatic lesions. Based on expression profiles, CDK inhibitors may have activity in PR negative tumours, supporting further testing in clinical trials for patients with systemic endometrial cancer dependent on PR status.
OBJECTIVE: In endometrial cancer loss of progesterone receptor (PR, gene name PGR) is associated with aggressive disease and altered response to hormonal treatment. The aim of this study was to investigate changes in PR expression level with disease progression, and explore whether differences in gene expression according to PR status can be linked to processes involved in cancer development elucidating new therapeutic opportunities. METHODS: 686 primary endometrial cancers and 171 metastatic lesions were investigated for PR expression in relation to clinical and histopathological data. Protein levels were investigated by immunohistochemistry and reverse phase protein array, and mRNA levels by DNA oligonucleotide microarray. RESULTS:PR protein level was significantly associated with PGR mRNA expression (P<0.001) and patient survival (P<0.001). Loss of PR increased with disease progression, with 23% of the primary tumours and 76% of metastases demonstrating PR loss. Using a cell cycle progression signature score, PR loss was associated with increased proliferation for both oestrogen receptor (ER) positive and negative tumours. Through a Connectivity Map search, CDK inhibitors and other drugs with anti-proliferative effects were suggested in particular for treatment of patients with loss of PR. CONCLUSION: Loss of PR in endometrial cancer is associated with increased proliferation, poor survival, and increases from primary to metastatic lesions. Based on expression profiles, CDK inhibitors may have activity in PR negative tumours, supporting further testing in clinical trials for patients with systemic endometrial cancer dependent on PR status.
Authors: Rameen Beroukhim; Helga B Salvesen; Frederik Holst; Henrica M J Werner; Siv Mjøs; Erling A Hoivik; Kanthida Kusonmano; Elisabeth Wik; Anna Berg; Even Birkeland; William J Gibson; Mari K Halle; Jone Trovik; Andrew D Cherniack; Karl-Henning Kalland; Gordon B Mills; Christian F Singer; Camilla Krakstad Journal: Clin Cancer Res Date: 2018-11-15 Impact factor: 12.531
Authors: Jeffery M Vahrenkamp; Chieh-Hsiang Yang; Adriana C Rodriguez; Aliyah Almomen; Kristofer C Berrett; Alexis N Trujillo; Katrin P Guillen; Bryan E Welm; Elke A Jarboe; Margit M Janat-Amsbury; Jason Gertz Journal: Cell Rep Date: 2018-03-13 Impact factor: 9.423
Authors: Gonda Konings; Linda Brentjens; Bert Delvoux; Tero Linnanen; Karlijn Cornel; Pasi Koskimies; Marlies Bongers; Roy Kruitwagen; Sofia Xanthoulea; Andrea Romano Journal: Front Pharmacol Date: 2018-09-19 Impact factor: 5.810
Authors: Anna Berg; Erling A Hoivik; Siv Mjøs; Frederik Holst; Henrica M J Werner; Ingvild L Tangen; Amaro Taylor-Weiner; William J Gibson; Kanthida Kusonmano; Elisabeth Wik; Jone Trovik; Mari K Halle; Anne M Øyan; Karl-Henning Kalland; Andrew D Cherniack; Rameen Beroukhim; Ingunn Stefansson; Gordon B Mills; Camilla Krakstad; Helga B Salvesen Journal: Oncotarget Date: 2015-01-20
Authors: Tae Hoon Kim; Jung-Yoon Yoo; Zhong Wang; John P Lydon; Shikha Khatri; Shannon M Hawkins; Richard E Leach; Asgerally T Fazleabas; Steven L Young; Bruce A Lessey; Bon Jeong Ku; Jae-Wook Jeong Journal: PLoS Genet Date: 2015-09-17 Impact factor: 5.917
Authors: Ana Laura Saraiva; Rita Payan-Carreira; Fátima Gärtner; Marta R Fortuna da Cunha; Alexandra Rêma; Fátima Faria; Lígia M Lourenço; Maria Dos Anjos Pires Journal: BMC Vet Res Date: 2015-08-14 Impact factor: 2.741
Authors: Carla Bartosch; Sara Monteiro-Reis; Renata Vieira; Armindo Pereira; Marta Rodrigues; Carmen Jerónimo; José M Lopes Journal: PLoS One Date: 2015-08-07 Impact factor: 3.240
Authors: A M Kamal; J N Bulmer; S B DeCruze; H F Stringfellow; P Martin-Hirsch; D K Hapangama Journal: Br J Cancer Date: 2016-03-01 Impact factor: 7.640